Randomised trials at the level of the individual by Park, Jay J H et al.
eCommons@AKU 
Centre of Excellence in Women and Child 
Health Centres of Excellence 
5-1-2021 
Randomised trials at the level of the individual 




Rebecca F. Grais 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/coe-wch 
 Part of the Clinical Trials Commons, Maternal and Child Health Commons, and the Women's Health 
Commons 
Authors 
Jay J H. Park, Nathan Ford, Denis Xavier, Per Ashorn, Rebecca F. Grais, Zulfiqar Ahmed Bhutta, Herman 
Goossens, Kristian Thorlund, Maria Eugenia Socias, and Edward J. Mills 
www.thelancet.com/lancetgh   Vol 9   May 2021 e691
Series
Clinical Trials in Global Health 2
Randomised trials at the level of the individual
Jay J H Park, Nathan Ford, Denis Xavier, Per Ashorn, Rebecca F Grais, Zulfiqar A Bhutta, Herman Goossens, Kristian Thorlund, 
Maria Eugenia Socias, Edward J Mills
In global health research, short-term, small-scale clinical trials with fixed, two-arm trial designs that generally do 
not allow for major changes throughout the trial are the most common study design. Building on the introductory 
paper of this Series, this paper discusses data-driven approaches to clinical trial research across several adaptive 
trial designs, as well as the master protocol framework that can help to harmonise clinical trial research efforts in 
global health research. We provide a general framework for more efficient trial research, and we discuss the 
importance of considering different study designs in the planning stage with statistical simulations. We conclude 
this second Series paper by discussing the methodological and operational complexity of adaptive trial designs 
and master protocols and the current funding challenges that could limit uptake of these approaches in global 
health research.
Introduction
Randomised clinical trials are an underused tool in global 
health research that have the potential to drive evidence-
informed policy making in low-income and middle-
income countries (LMICs). Panel 1 shows the findings of 
systematic searches of trials from two key areas of global 
health: maternal, newborn, and child health, and malaria. 
Most global health trials have a simple fixed design that 
uses two arms, is typically small in sample size (less than 
100 patients), and is underpowered. Although many trials 
have been under taken in these research areas, the 
information derived from these trials is inconsistent and 
might suggest the need for both better trial planning and 
coordination.
Newer approaches for the planning and implementation 
of trials than these fixed, two-arm designs are currently 
being used by specialised trialist groups that are 
largely based in (and working in) the USA and 
the UK. Alternative design choices include data-driven 
approaches in clinical trial research that are known as 
adaptive trial designs. An adaptive trial design is a type of 
trial design that allows for prespecified adaptations 
throughout the trial, in which the decision to adapt is 
dependent on the interim data collected.5,6 Particularly 
when epidemiology is poorly understood and sample 
size calculations are challenging, this type of trial can 
minimise the limitations conferred by fixed trial designs 
by planning for possible changes and methods of 
evaluating interim data through extensive simulations.7,8 
Because there are many unknowns and difficulties in 
trial planning in LMICs, simulations can be a powerful 
tool that can enable more efficient and ethical clinical 
trial research for global health research.9 Simulations can 
help to avoid trial design decisions that trial investigators 
might later regret, after the trial shows negative findings 
(areas of anticipated regret).7 Whether the design is 
adaptive or not, simulations can be used for any designs 
and any clinical areas of research, but they are not often 
used in the context of global health.9
Adopting the framework of master protocols (which 
have also been referred to as core protocols) might help to 
minimise the fragmented nature of research efforts within 
the global health trial landscape. The term master protocol 
generally refers to a single overarching protocol that has 
been developed to evaluate multiple inter ventions, with a 
general goal of improving efficiency and standardisation 
in clinical research.10–14 Compared with conventional 
clinical trials, master protocols are planned to be larger in 
scale and offer flexibility and sustainability in answering 
multiple research questions over longer periods of time 
under a single protocol.14,15 A landscape analysis of master 
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Key messages 
• An adaptive trial design is a validated method that has 
been used extensively but, in the past 30 years, this 
approach has predominantly been used for pharmaceutical 
therapeutic research under regulatory scrutiny in high-
income countries. Consideration of data-driven 
approaches might become increasingly important for 
global health trial investigators working in low-income 
and middle-income countries.
• No trial designs should be used by default. Instead, trial 
planning practices should include considerations of 
multiple designs and the possibility of using statistical 
simulations to inform efficient trial designs for the given 
clinical question in conjunction with other factors.
• The principles of master protocols and their subtypes in 
basket, umbrella, and platform trials can be tailored and 
adapted to suit the needs of a multitude of health 
problems. Such study designs might not only improve the 
quality and standardisation of trial research but could also 
help in reinforcing local infrastructure and improving 
training and professional development opportunities, 
particularly in low-income and middle-income countries, 
given that master protocol studies are generally planned to 
be large in scale and long term.
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protocols by use of a systematic literature review has 
shown a rapid increase in the use of these designs, but 
their application has largely been limited to research being 
done in high-income country (HIC) settings.15
This Series paper builds on the discussion from the first 
paper9 of this Series. We first introduce the concepts of 
adaptive trial designs and master protocols, and we 
present specific study designs that can be applied in global 
health research. We discuss how the master protocol 
framework can be used to promote sustainability and 
holistically improve trial research in LMICs. We outline a 
general framework for improved trial planning and future 
considerations that both researchers and funding bodies 
can make to improve global health research.
Adaptive trial designs for global health
Overview of adaptive trial designs
In global health research, there are often many instances 
of substantial uncertainty regarding the natural history 
of the diseases and how best to intervene. As a result, 
assumptions with a high degree of uncertainty might be 
required, which can often be challenging to plan and 
design trials. Therefore, it is important to use clinical 
trial simulations to explore a multitude of scenarios to 
guide the selection of trial design parameters while 
considering different trial designs, to determine the 
optimal design for a given research question.
The default use of fixed trial designs can pose 
considerable inefficiencies that cannot easily be afforded 
in the context of constrained funding, as often applies to 
global health research. In clinical trials with fixed trial 
designs, the data are not typically evaluated until the last 
participant has finished their follow-up. Adaptive trial 
designs allow for more frequent learning by implementing 
preplanned interim evaluations that use prespecified 
decision rules.8,16 The ongoing learning nature of adaptive 
trial designs can test for the adequacy of the assumptions 
that the investigators have made going into the trial 
early, such that modifications to the trial designs can 
be made, to increase the likelihood of detecting a true-
positive effect or stopping the trial early if the intervention 
is shown to be futile.
Although there might be potential concerns for 
investigator bias, adaptive trial designs are protocol-
driven.8,16 The specific design components are not 
modified by the trial investigators.17 There are explicit 
plans for interim evaluations, potential adaptations, and 
decision rules that are written into the trial protocol 
before any participants are recruited into the trial.8,16 
If any of the predetermined decision rules are met during 
an interim analysis, adaptations are made as planned, to 
avoid undermining the trial’s validity and integrity.18 
Interim analyses are often done by independent statis-
ticians and reviewed by an independent data monitoring 
committee.18–21 Data monitoring committees are often 
staffed by scientists and statisticians from HICs, but it 
is important for clinical trials set in LMICs to have 
representation of data monitoring committee members 
from the LMICs.
Sample size re-estimation
Sample size calculation is an important part of trial 
planning. Typically, little information is available 
with regard to baseline disease prevalence, anticipated 
dropout, loss to follow-up and other features essential 
for sample size calculations. As such, determining 
sample size calculations can be a difficult task; trial 
investigators in global health research undertake sample 
size calculations with assumptions that are justified with 
the use of a mixture of subjectivity, external studies with 
limited generalisability to the setting of interest, or small-
scale pilot studies or proof-of-concept studies with high 
degrees of uncertainty. Sample size re-estimation can be 
a valuable tool for increasing the probability of detecting 
treatment effects. Sample size re-estimation is a type of 
adaptive trial design that allows for modification of the 
sample size target based on interim data.22 If the event 
rate is shown to be lower than foreseen at the interim 
analysis, the trial’s statistical power will consequently 
be lower than originally planned. Adaptive trials with 
Panel 1: Assessment of individually randomised global health clinical trials carried 
out in low-income and middle-income countries (LMICs)
Methods
To assess design characteristics of individually randomised clinical trials that are carried out 
in LMICs, we focused on two key research areas within global health: maternal, newborn, 
and child health (MNCH), and malaria. For MNCH, we included LMIC-based individual 
randomised clinical trials that investigated interventions under the domains of 
micronutrients, balanced energy protein or food supplements, deworming, maternal 
education for adverse birth and linear growth outcomes during pregnancy, exclusive 
breastfeeding, and complementary feeding periods (ie, first 1000 days of life). For malaria, 
we included intermittent preventive therapies in the form of antimalarial drugs for 
pregnant women, infants, and children residing in LMICs. These trials have been identified 
from systematic reviews that have been published between 2017 and 2019.1–4 A total of 
190 LMIC-based trials published in these two research areas (158 MNCH trials 
and 32 malaria trials) were included for this assessment. The list of included trials is 
provided in the appendix (pp 6–14).
Number of interventions, sample size, and trial duration
The modal (ie, most frequent) number of interventions investigated in these global health 
trials is two (IQR 2–3), meaning two-arm trials were most often undertaken. The median 
sample size was 441 (IQR 204–1134). The median trial duration was 22·0 months 
(13·0–37·0).
Trial planning practices
132 trials studied a continuous outcome as the primary outcome and 58 trials studied a 
binary outcome as the primary outcome. 41 (22%) of the 190 trials did not report any details 
on their sample size justification (38 MNCH trials and three malaria trials). Only 65 (34%) of 
190 trials in these key areas within global health adequately reported their sample size 
calculation. For instance, of the 132 trials with a continuous primary outcome, 43 (33%) 
reported on the assumed effect size and expected dispersion (eg, standard deviation) of the 
primary outcome. Among assessable trials that studied binary outcomes, only 22 (38%) of 
58 trials reported on their assumed treatment effect size and baseline control event rates.
See Online for appendix
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planned sample size re-estimation would allow for the 
target sample size to be increased to improve the trial’s 
statistical power.
Seamless designs
For drug development, clinical trial investigations are 
usually done in phases, with earlier phases undertaken 
with exploratory purposes (eg, testing of dose ranges), 
followed by a confirmatory phase 3 trial that can provide 
strong evidence of drug efficacy or safety, or both.23 With 
conventional approaches to clinical trial evaluation, the 
knowledge from each phase can only be used after the 
trial is finished.16 Even if an early exploratory clinical trial 
is undertaken and shows results that are promising 
enough to justify a further confirmatory trial, clinical 
evaluation of such an intervention would be paused 
between the two clinical trials. However, a seamless 
design is a type of trial design that allows for a trial in 
the non-confirmatory stages to immediately continue 
onto the subsequent trial.16,24 The most commonly used 
seamless designs are seamless phase 2 to phase 3 trials, 
because phase 2 and phase 3 can have considerable 
overlaps in essential components (eg, clinical settings).24
Seamless designs can be useful for global health 
research. For vaccine development, as one example, the 
efficiency of trial investigation of candidate vaccines 
can be improved by use of the seamless phase 2 to 
phase 3 approach that has been used for a clinical 
evaluation of the 9-valent human papillomavirus vaccine 
by Joura and colleagues.25 Before this adaptive trial with a 
seamless design was undertaken, there was uncertainty 
about an optimal dose of the 9-valent human papilloma-
virus vaccine; therefore, this seamless trial began with a 
phase 2 stage that assessed three dosages (low, medium, 
and high) and immunological endpoints were used to 
select the optimal dosage for the subsequent phase 3 
stage.25 The medium-dose vaccine, which showed 
adequate immunogenicity and safety profiles, was then 
seamlessly transitioned into a phase 3 trial, in which it 
was tested and confirmed for non-inferiority against the 
standard-of-care vaccine (4-valent human papillomavirus 
vaccine). The seamless design substantially shortened 
the amount of time to complete a conclusive phase 3 
trial, given that there was no pause between phase 2 and 
phase 3.25,26
The nomenclature of different clinical trial phases 
developed under the drug development framework 
might not apply to all global health research. However, 
similar to early stage clinical trials for drug develop-
ment, early stage exploratory trials evaluating non-
pharmaceutical inter ventions in global health should 
be more concerned with false-negative discoveries. 
Because confirmatory trials require more resources 
than exploratory trials, undertaking exploratory trials 
before committing resources for confirmatory trials 
is important. Instead of undertaking exploratory and 
confirmatory trials separately, adopting seamless designs 
in which the exploratory stage can seamlessly continue 
onto the confirmatory stage (when positive findings are 
shown from the exploratory stage) could expedite clinical 
evaluations in global health research.
Response-adaptive randomisation (RAR)
RAR is a type of adaptive trial design in which allocation 
ratios can be adapted on the basis of interim analyses 
over the course of the trial.16,27 The allocation ratio is 
adapted to favour the allocation of future participants 
into the intervention arms with more favourable interim 
results.16,27 When a clinical trial investigation is done on 
potentially life-saving therapies for deadly illnesses, RAR 
can have a great appeal.28 For example, these type of 
adaptations might be important for candidate thera-
peutics to treat Ebola and COVID-19.29,30 Clinical trials 
with RAR can potentially minimise the number of 
participants assigned to control groups or other inferior 
arms.31 However, there are risks for bias and inefficiencies 
that might be introduced from having poorly planned 
RAR. These designs for two-arm trials will have 
lower statistical power than parallel-allocation designs 
(eg, 1:1 allocation). In multiarm trials, RAR can improve 
the probability of selecting the optimal treatment arm, 
given that allocation to the control is adequately 
maintained or even increased to match the allocation 
ratio of the best-performing intervention arm.32 To 
prevent bias that could arise due to poorly planned RAR 
algorithms, extensive rounds of simulations should be 
used to identify robust statistical constraints.8,16 It is also 
important to recognise the challenges of implementing 
RAR designs in resource-limited regions. For instance, 
obtaining informed consent is already a difficult task in 
global health research set in LMICs because many trials 
in these settings involve vulnerable populations, such as 
children. Given that these populations might have a 
varied understanding of research intent or conduct, RAR 
designs can raise complexities of obtaining consent from 
participants.33
Interim analyses for stopping trials early 
Adopting interim analyses that allow for individual 
intervention arms or the trial itself to be stopped early 
can improve the ethics and efficiency of clinical trials for 
global health research. Interim evaluation in this context 
would involve generating performance metrics on the 
effectiveness and not just monitoring the trial progress 
from the data that are collected. Stopping a trial early 
could be due to superiority reasons, if the interim data 
show that the intervention has sufficient evidence to 
conclude that it is effective. For example, the HIV 
trial of male circumcision in South Africa (ANRS 1265) 
was ended early for superiority on the basis of an interim 
analysis undertaken when 63% of the total planned 
person-years had been observed.34 However, if the 
interim data show that a given intervention has 
inadequate benefit or sufficient activity, the trial can be 
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stopped early for futility. In a 2020 large-scale HIV vaccine 
trial (HVTN 702) undertaken in South Africa, the 
independent data monitoring committee reported no 
benefits of the HIV vaccine when an interim analysis 
showed a similar number of infections in the vaccinated 
(n=129) and placebo (n=123) groups.35
Interim analyses for stopping trials early for either 
superiority or futility can improve the core ethical 
requirement of protecting research participants who 
deserve special considerations, such as child populations. 
Although it is commonly believed by researchers that 
individuals will enrol in clinical trials under the belief that 
their participation will help advance science,36 this is not 
often the case. Participants might agree to enrol in a 
clinical trial with a belief that they will gain personal 
benefit in return for their participation, because their 
participation could lead to access to clinical care and other 
benefits that they would not normally have, which is 
particularly likely in places where people have inadequate 
health-care access or care is of poor quality (which are 
contexts that are often targeted in global health research).37 
Participants might be exposed to unknown risks given the 
experi mental nature of clinical trial research, particularly 
in therapeutic interventional trials.37 Many clinical trials 
involve marginalised and vulnerable populations that 
might have a poor under standing of the research intent or 
conduct.38–40 This was the case for three early trials of pre-
exposure prophylaxis for the prevention of HIV in 
Cambodia, Nigeria, and Cameroon, where ethical concerns 
for minimal engagement in care post-trial were cited as the 
primary reasons for stopping the studies early.41
There are several statistical methods for stopping trials 
early. There are group sequential designs that allow for 
trials to be stopped early if the test statistic, which 
corresponds to a p value, exceeds a specified boundary 
(a crucial value used to determine significance level) at a 
preplanned interim analysis.42 To ensure that the overall 
type I error rate does not exceed the desired α (eg, 5%), the 
stopping boundaries are usually set more stringently at the 
interim analyses. More stringent stopping boundaries are 
used at interim analyses to account for multiplicity 
(inflated errors due to multiple testing), to control for the 
overall type I error rate.42 Stopping rules under the Bayesian 
framework can also be implemented by prespecifying 
decision rules that are specified in terms of probabilities.43,44 
For instance, an adaptive Bayesian trial might allow for the 
trial to be stopped early on the basis of superiority if the 
estimated probability of success exceeds a threshold; 
stopping trials early for futility can also be permitted if the 
estimated probability of success falls below a specific 
threshold.44 These thresholds for superiority and futility 
are usually determined with statistical simulations that 
yield desired operating characteristics.44
Other reasons for stopping trials early
In addition to superiority and futility reasons, there are 
other reasons to end trials early. Regardless of design, 
careful attention is required to monitor adverse events 
among participants during the trial, to allow for valid 
assessment of harm. If an intervention is shown to be 
harmful, early termination of the trial (or discontinuation 
of the intervention arm in multiarm trials) could occur. 
Measures to stop trials for adverse events are already 
commonly implemented in global health research. A 
trial might also end early if there are recruitment 
challenges that can prevent the trial from finishing in a 
timely manner. Recruitment is often a major challenge 
for clinical trials undertaken in HICs.45,46 However, 
LMICs might not have similar recruitment challenges 
since there is often a higher burden of certain diseases.47,48 
For low-prevalence diseases, such as neglected tropical 
diseases, it is important to consider whether it is feasible 
to recruit enough participants to answer the research 
question reliably in the geographical setting.
There might be external reasons for ending trials early. 
If new results from equivalent external studies become 
available, there might no longer be clinical equipoise for 
the intervention under study, raising ethical issues in 
continuing the trial. This circumstance can impose a 
serious ethical issue for participants randomised to the 
control group, placebo, or outdated standard of care who 
are undergoing clinical follow-up, as well as for future 
participants who might be randomised to this less effective 
(or even dangerous) control group.49,50 Additionally, with 
other external developments (eg, alternative disease 
control measures), the intervention being evaluated might 
no longer be important.
Master protocol framework for global health
The current approach
In global health research, two-arm clinical trials that 
compare one experimental intervention with the 
standard of care or placebo (as the control group) are the 
most often used study design (panel 1). Because there 
are usually multiple intervention candidates in a given 
research area, this can result in multiple trials being 
undertaken independently, with redundant infra-
structures created between different trials. These trials 
also often have different, non-standardised operational 
procedures; therefore, determining what the optimal 
intervention for a given condition is becomes difficult 
when the evidence comes from multiple heterogeneous 
two-arm trials.51 Some of the current challenges in global 
health research that arise from the preponderance of 
two-arm trials might be overcome by imple menting 
multi arm trials, particularly well designed platform 
trials.52
Different types of master protocols
Master protocols are often categorised as platform trials, 
basket trials, and umbrella trials (figure 1). Because 
misunderstanding of master protocols is common, the 
detailed descriptions of the key concept of platform 
trials,53 as well as basket and umbrella trials,54 have been 
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described previously.14 In brief, a platform trial is a type 
of clinical trial in which multiple interventions can 
be evaluated simultaneously by use of a common 
control group within a single master protocol that 
shares the same infrastructure with standardised trial 
procedures.14,15,53 In addition to multiple interventions 
undergoing multiple interim evaluations simultaneously, 
platform trials have the additional flexibilities of allowing 
new experimental arms to be added and for the control 
arm to be updated if the standard of care changes 
throughout the trial.14,15,55–59 Platform trials can minimise 
the number of participants allocated to the control group 
by having a common control group. These trials allow for 
multiple interventions to be evaluated in a perpetual 
manner while collecting high-quality data that will enable 
comparisons of the interventions that might be highly 
relevant in informing new policy changes in global 
health. For instance, the randomised evaluation of 
COVID-19 therapy (RECOVERY) trial (ISRCTN50189673 
and NCT04381936) is a large, ongoing, adaptive 
platform trial based in the UK, and this trial has 
produced important clinical trial evidence that has led to 
improved inpatient management of patients with 
COVID-19 worldwide (discussed further in the fourth 
paper of this Series60).
Compared with platform trials, basket trials and 
umbrella trials are designed to identify therapies that can 
specifically affect disease targets (targeted therapies), to 
improve the treatment of diseases.54 Basket trials evaluate 
a targeted therapy for multiple diseases that share 
common disease targets, whereas umbrella trials are 
designed to evaluate multiple targeted therapies for a 
single disease that is stratified into multiple subgroups.54 
Because these disease targets are usually determined by 
their genetic make-up, basket and umbrella designs have 
predominantly been used in oncology research as 
biomarker-guided trials.14,15 An example of a therapeutic 
umbrella trial undertaken in LMICs for HIV is discussed 
in panel 2.
Platform, basket, and umbrella trials are often 
organised and planned with a modular protocol 
structure, with the master protocol containing all generic 
elements of the trial and intervention appendices that 
are specific to each active intervention.7 With the use 
of a modular format, adding a new intervention or 
discontinuing a current intervention can become more 
operationally seamless because the main study master 
protocol does not need to be updated every time a new 
intervention is added or discontinued in platform trials. 
In basket and umbrella trials, common screening 
mechanisms with standardised laboratory procedures 
are used in different institutions and across different 
geographical settings under one single master protocol. 
This standardisation in operating procedures can help to 
provide harmonisation of clinical trial research efforts 
across different geo graphical settings in the global 
health field.
Benefits of a master protocol framework for 
global health
Trials planned under the master protocol framework are 
usually planned for the long term by forming a large trial 
network across and throughout multiple institutions.13–15,62 
Given that common standardised operating procedures 
are established in multiple institutions through the 
master protocol, the master protocol framework can allow 
for a large amount of high-quality data to be collected.14,15 
The research institutions can also more easily overcome 
the issues of external changes that might occur during 
the trial.63–65 Should a new therapeutic discovery be made 
after a clinical trial begins, instead of launching a new 
clinical trial, the new intervention can be added into the 
trial and, if there are new changes in clinical practices, 
these changes could be better adopted into the master 
protocol and its standardised operating procedures.14,15
Insufficient or poorly organised infrastructure and low 
human resource capacity for research are often cited 
reasons as to why high-quality clinical trials are more 
difficult to carry out in LMICs than HICs. However, 
clinical trials in global health research are almost always 
undertaken without any long-term consideration of 
infrastructure and human resources in LMICs and the 
likely substantial involvement of external actors in these 
Figure 1: Master protocols: basket trials, umbrella trials, and platform trials
Master protocols refer to a single overarching protocol that has been developed to evaluate multiple hypotheses, 
with the general goal of improving efficiency and establishing uniformity through standardisation of procedures in 
the development and evaluation of interventions. Master protocols are often classified into basket trials, umbrella 
trials, and platform trials. Basket trials refer to designs in which a targeted therapy is evaluated for multiple 
diseases that share common molecular alterations or other risk factors. Umbrella trials evaluate multiple therapies 
for a single disease that is stratified into different groups on the basis of molecular alterations or other risk factors. 
However, platform trials have the flexibility of dropping ineffective interventions and adding new interventions 
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settings. Many regions in LMICs have not been given a 
long-term opportunity to build and maintain ongoing 
infrastructure that would also allow for local capacity 
building to be leveraged at the same time. Instead, 
historically when a clinical trial finishes, the infrastructure 
usually disappears along with the research opportunities 
for the local researchers. For many, this outcome results 
in temporary unemployment and, sometimes, reticence 
to participate in future clinical trials. For clinical trialists 
initiating a new trial, recruiting experienced staff is 
challenging and could delay the trial start date.
Given that master protocols are perpetual in nature, the 
master protocol framework can help with the capacity 
building and retention of trained staff under a large, 
planned collaboration that recruits staff into secure roles 
for a fixed but long period, in which multiple questions 
can be addressed over time in one single trial. If the long-
term goal is to build the capacity for clinical research 
in LMICs, then planning for long-term employment is 
necessary to offer professional development oppor-
tunities. Undertaking one large trial under the master 
protocol framework can also save on resources that are 
required in setting up multiple independent clinical 
trials, and savings should be diverted to the health-care 
professionals based in the sites of investigation, and this 
framework can identify and address gaps in the research 
infrastructure that are common barriers to undertaking 
clinical trials in LMICs.
This cost-saving, which is both a feature of direct and 
indirect benefits, can instead be diverted to building 
human resource capacity and research infrastructure in 
LMICs. In addition to staff training and capacity building, 
acquisition costs for specialised equipment can be 
consolidated. For example, the WHO Stepwise Laboratory 
Quality Improvement Process Towards Accreditation in 
the African region (also known as SLIPTA) initiative66 has 
specifically mentioned the need for experts and centres 
of excellence in LMICs to improve disease prevention 
and control. The systemic longevity and specialised 
methodologies intrinsic to many master protocols should 
be well aligned with pre-existing efforts, such as 
the African Strategies for Advancing Pathology,67 to build 
on the unique opportunities that the master protocol 
framework can provide.
Panel 2: HIV umbrella trial from South Africa (ACTG A5288) 
To our knowledge, ACTG A5288 was one of the first umbrella 
trials in low-income and middle-income countries (LMICs) to 
evaluate new approaches for differentiated care in settings 
where they have not been routinely used before.61 In this trial, 
Grinsztejn and colleagues61 used the available knowledge on 
antiretroviral therapy (ART) and real-time drug resistance 
genotype monitoring to develop new third-line ART strategies 
for people living with HIV at 19 urban sites in ten LMICs, 
specifically in Africa (Kenya, Malawi, South Africa, Uganda, and 
Zimbabwe), Latin America (Brazil, Haiti, and Peru), and 
southeast Asia (India and Thailand). In this trial, patients who 
had an inadequate response to second-line therapies and who 
had varying resistance and susceptibility to different ARTs were 
differentiated into four main cohorts (A, B, C, and D), with a 
randomised mobile phone adherence support evaluation 
embedded within the overall design. Participants who did not 
show resistance to lopinavir (a second-line ART) were assigned 
to cohort A, in which they continued to receive a second-line 
ART. Participants resistant to lopinavir without resistance to 
etravirine (a second-line ART) were assigned to cohort B. 
Participants in cohort B without detectable hepatitis B surface 
antigen were randomly assigned either to a best available 
nucleoside reverse transcriptase inhibitor plus ritonavir-
boosted darunavir plus raltegravir as cohort B1, or ritonavir-
boosted darunavir plus raltegravir plus etravirine as cohort B2; 
and those with detectable hepatitis B surface antigen were 
assigned to cohort B3  to receive ritonavir-boosted darunavir 
plus raltegravir and either tenofovir plus emtricitabine or 
tenofovir plus lamivudine as an observational cohort. 
Participants with resistance to etravirine and lopinavir or all 
nucleoside reverse transcriptase inhibitors were assigned to 
cohort C to receive ritonavir-boosted darunavir plus raltegravir 
plus tenofovir plus lamivudine, and those who were ineligible 
for cohorts A, B, and C were assigned to cohort D to receive the 
best available nucleoside reverse transcriptase inhibitors plus 
ritonavir-boosted darunavir plus raltegravir.
Between January, 2013, and September, 2015, 545 participants 
were enrolled into this umbrella trial. 287 (53%) of 
545 participants were assigned to cohort A; 154 (27%) of 
545 participants were randomly assigned to either cohort B1 
(74 [14%] of 545 participants) or cohort B2 (72 [13%] of 
545 participants), and 8 (1%) of 545  participants were assigned 
to cohort B3. 70 (13%) of 545 participants were assigned to 
cohort C and 34 (6%) of 545 participants were assigned to 
cohort D. In this trial, 424 (78%) of the 545 participants who 
did not respond to second-line ART had at least one mutation 
to nucleoside reverse transcriptase inhibitors, non-nucleoside 
reverse transcriptase inhibitors, or protease inhibitors. 
Only 146 (27%) of the 545 participants had thymidine analogue 
mutations known to cause a reduction of ART activity.
Understanding each patient’s treatment history and their 
genotype is paramount to define future regimens. This 
understanding becomes complicated in non-research settings 
because of low coverage of and access to viral load monitoring 
and low capacity for real-time genotyping in most LMICs. Given 
the need to offer regimens based on treatment history, umbrella 
trials allow for targeted strategies that allow clinicians to interpret 
signals about whether more or less favourable outcomes occur in 
the targeted populations. The assembled infrastructure and 
capacity to carry out real-time genotyping in LMICs can help to 
improve the clinical services in these resource-limited settings.
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Perpetual clinical trials allow for the long-term 
involvement of the community in the planning of future 
clinical trials. For these perpetual clinical trials to be 
meaningful, the scope of research should be driven by 
local researchers, to correctly target areas that are key 
priorities in the location of the trial. Key community 
members (eg, trusted community health-care workers) 
represent important knowledge translation agents of 
the trial conduct and study findings for the affected 
populations. Long-term trust can encourage participant 
enrolment, retention, and involvement of the dissemi-
nation of study findings. Mechanisms to engage with local 
institutions and ethics review boards can be implemented 
to enable dialogue around changes in the conduct and 
evaluation of the trials, to ensure ethical conduct.
General framework for more efficient trials in 
global health
There are several important questions for clinical trial 
research that deserve consideration during the planning 
stage (panel 3). These questions can serve as a general 
framework to improve the efficiency of trials, in global 
health research and beyond.
In the planning stage, it is important to identify areas 
of uncertainty and anticipate different scenarios with 
possible trajectories that might be observed during 
the trial. There should be extensive discussions with 
clinical experts based in the area that the trial will be set, 
and with key opinion leaders with geographical and 
sociocultural familiarity with that area.
There should be early discussions to identify admin-
istrative structures and logistics of data collection, 
monitoring, and implementing adaptations that could 
potentially limit the feasibility of undertaking an adaptive 
clinical trial.68 Administrative and operational logistic 
factors (eg, expected recruitment time and time to 
implement adaptations) should be discussed with local 
stakeholders and clinical staff who will be responsible for 
managing the day-to-day operations of the clinical trial. If 
the outcome for the prespecified adaption takes a long 
time to measure in comparison with the recruitment 
time, adaptive trial designs might not be feasible because 
the planned recruitment might be completed before a 
sufficient number of clinical outcomes can be observed.68
Whether they are adaptive or not, clinical trial 
simulations can be used for any trial design and any areas 
within the global health field.9 These tools allow trial 
investigators to explore, compare, and better understand 
the fragility of assumptions, to produce the most optimal 
trial design for a given research question.69–71 Simulations 
allow for an assessment of different designs, including 
fixed trial designs, for their operating characteristics 
(eg, expected sample size, type I error rates, and statistical 
power) under several scenarios.71 Simulations can also be 
used to assess other metrics (eg, estimated number of 
interventions and placebo doses required), to improve 
resource and operational planning of the trial.71,72
Good simulation practices that have been described for 
pharmaceutical development can be extended to global 
health research.71 Clinical trialists and clinicians involved 
in the trial do not need to understand every aspect of the 
statistical assumptions and underlying technical details to 
partake in group discussions during the planning stage. 
Because simulations are an iterative process, the initial 
group discussion on simulation can start with simple 
simulations to engage the local clinical experts and key 
opinion leaders and help them to become more familiar 
with interpreting trial simulation results.8 Then, in 
subsequent rounds of simulations, more com prehensive 
simulations on other more complicated scenarios can be 
shared for feedback.8
Funders could promote the use of simulations and 
thus more efficient trial planning for global health 
research if the funders place a requirement for 
simulations to be included as part of the application 
process instead of just simple sample size calculations. 
For instance, when the US Food and Drug Administration 
recognised the value of simulations and emphasised 
their use in trial planning, this recognition catalysed the 
use of simulations in the pharmaceutical industry.7,73 
Across different LMICs, promotion of simulations will 
most likely require collaboration and communications 
between different donors, regulatory authorities, and 
global health organisations.
Challenges with adaptive trial designs and 
master protocols
Methodological and operational complexity
Adaptive trial designs and master protocols can be 
inherently more methodologically and operationally 
Panel 3: General considerations for efficient clinical trial 
research 
1 Does the trial ask a question on which there is genuine 
uncertainty and is the trial design appropriate for 
answering the question?
2 Does the trial use a control intervention that reflects 
routine care?
3 Is the trial evaluating interventions that are feasible for 
use in the setting?
4 Does the trial enrol the population that is most likely to 
benefit from the results of the trial (show treatment effect)?
5 Have the investigators examined all important 
uncertainties in the planning stage (eg, examined 
different control event rates to see how they affect the 
statistical power)?
6 Have the investigators planned for areas of anticipated 
regret and other unanticipated changes (eg, planned and 
implemented a sample size re-assessment during the trial 
to avoid anticipated regret)?
7 Have the investigators planned for continuity of the 
treatment or approach to the trial?
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complex than conventional fixed trial designs. Incorrectly 
planned or executed adaptive trial designs can introduce 
statistical and operational biases.74 Although more time 
and resources will be dedicated to the planning stage, 
this is a far preferable alternative than the current norm 
of insufficient trial planning practices that occur too 
frequently in all areas of clinical trial research, including 
in the global health field. Consolidating resources and 
collaborations across a wider network of researchers and 
institutions from different geographical regions will be 
important for global health research. Instead of creating 
different control groups, having a common control group 
can be more statistically efficient. Geographical variability 
could also be better represented by master protocols 
because standardised operating procedures will be 
implemented across different institutions, to record the 
data into a common centralised database.
Undoubtedly, implementing master protocols will have 
considerable logistic and operational challenges. For 
instance, there will be different standards of care across 
different countries and geographical settings. However, 
this challenge is not new: many multicentre, multi-
national clinical trials have successfully overcome similar 
problems. The rationale for adding a new intervention 
and the mechanisms should be discussed early with the 
ethics and regulatory bodies, to ensure that new 
interventions can be added in a timely manner.
We hope that these challenges will not be used as an 
argument to deter from the use of these innovative 
trial design approaches in global health research. Many 
of these operational challenges and barriers can be 
minimised in the planning stage by researchers based in 
the trial setting. Multidisciplinary collaborative efforts 
can easily overcome the planning challenges.
Funding challenges
In global health research, clinical trial funding pre-
dominantly relies on grants from government funding 
agencies and non-profit organisations, and the demand 
for funding by far exceeds supply. The funding value from 
the US National Institutes of Health, for example, is 
usually fixed for all applications that might vary in scope. In 
practice, clinical trial sample size and trial duration 
are limited due to budget constraints. Optimistic 
assumptions about the treat ment effects and baseline 
event rates are picked to justify the sample size that is 
suitable for the budget, to stay competitive during the 
application stage. For illustrative purposes, sample size 
and cost-savings are shown in figure 2. Master protocols 
and adaptive clinical trials might require more resources 
than the budget that is typically allowed by the funder.
Under the current funding scheme, the feasibility of 
undertaking these larger trials is limited even though 
such trials can improve efficiency and introduce other 
long-term benefits to staff who are based at the trial 
location and to local infrastructure. In clinical trials that 
are sponsored by the pharmaceutical industry, if the trial 
stops early for either futility or superiority, the remaining 
budget goes back into the research and development 
budget to finance other clinical trials. In publicly funded 
clinical trials for which securing funding is already so 
competitive, it is difficult to imagine academic research 
groups returning their funding, or the academic centres 
in HICs handing back their overheads to funders to be 
used to fund research centres in LMICs. For the global 
health funding agencies, it is important to consider 
funding long-term projects that can harbour data-driven 
techniques, to gain efficiencies as long-term investments 
that can harmonise and improve quality of clinical trial 
research while building research infrastructure and 
improving professional development opportunities in 
LMICs. Funding of long-term projects could be improved 
by better coordination between funding agencies, which 
can fund projects in prioritised clinical areas that align 
Figure 2: Comparison of two-arm, multiarm, and platform trial approaches on sample size and cost
For all scenarios, we assumed that there would be four experimental interventions that will be evaluated. 
We considered fixed trial designs, in which all clinical trials would end their recruitment in each arm when the 
target sample size of 650 patients was met. We assumed that a dichotomous outcome will be used as the primary 
outcome, with pairwise comparison with the control being planned as the primary analysis. The sample size per 
arm required to achieve 80% statistical power and 5% type I error rate was calculated by assuming an event rate 
of 40%, an effect size of 20% relative risk reduction, and 10% loss to follow-up rate. Because there are four 
independent trials being conducted in scenario 1, we defined the maximum total cost (direct and indirect cost) to 
be US$6·0 million assuming that each of the research grants will be for the amount of US$1·5 million. Detailed 
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with the changing disease burden in LMICs. This 
approach will require a conceptual change to mandate 
the funding to be allocated in ways that would catalyse 
infrastructure and professional development in LMICs.
Conclusion
Adaptive trial designs and master protocols have 
predominantly been used for research in HICs so far. 
Increasing awareness and understanding of these 
concepts will be crucial for global health researchers and 
their funders, to improve the efficiency and ethics of 
global health trials. Master protocol frameworks can help 
to improve the quality of clinical trial research by 
harmonising research efforts across different LMICs, 
and they could potentially be used to improve local 
infrastructure and offer more quality professional 
development opportunities at the trial setting.
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